• ” DT56a was effective against symptomatic vulvo-vaginal atrophy (vaginal dryness)…”

    NAMS Annual Congress 2011, book of abstracts

    Read More
  • “DT56a prevents postmenopausal osteoporosis.”

    BJOG. 2005;112(7):981-5

    Read More
  • “DT56a has anti-estrogenic properties in the breast tissue…”

    Eur J Obstet Gynecol Reprod Biol. 2007;130(1):140-1.

    Read More
  • “DT56a.. unique nature compared to the compounds currently used for postmenopausal osteoporosis by being bone-forming and not only an anti-resorptive agent”

    J Steroid Biochem Mol Biol.. 2006;98(1):90-6

    Read More
  • “Femarelle treatment in postmenopausal women increases BMD without unwanted estrogenic effect.”

    Menopause. 2003;10(6):522-5.

    Read More
  • “Treatment with DT56a resulted in a significant reduction of hot flushes in postmenopausal women… observed within the first month of treatment.”

    Climacteric. 2015;18(6):813-6

    Read More
  • “significant reduction in the Kupperman index following 12 weeks of treatment, which was sustained throughout the 12 months of treatment”

    Clin. and Exp. Ob. & Gyne. 2004;31(2):123-6.

    Read More
  • “Femarelle … inhibits menopausal symptoms without thrombogenicity…”

    Menopause 2011;18(3):285-288

    Read More
  • “DT56a decreased menopausal symptoms significantly and in the same degree as HT.”

    J Endocrinol Invest. 36(7):521-6

    Read More
  • Contact us

    Get Updates